{"id":"lecanemab-iv","safety":{"commonSideEffects":[{"rate":"12-21","effect":"Amyloid-related imaging abnormalities with edema (ARIA-E)"},{"rate":"17-18","effect":"Amyloid-related imaging abnormalities with microhemorrhages (ARIA-H)"},{"rate":"26-28","effect":"Infusion reactions"},{"rate":"9-12","effect":"Headache"},{"rate":"7-9","effect":"Flu-like illness"}]},"_chembl":{"chemblId":"CHEMBL3833321","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lecanemab selectively targets protofibrils, which are intermediate aggregates of amyloid-beta believed to be particularly neurotoxic in Alzheimer's disease. By binding to these protofibrils, the antibody facilitates their removal through microglial phagocytosis and peripheral clearance, thereby reducing amyloid burden in the brain and slowing cognitive decline in early symptomatic disease.","oneSentence":"Lecanemab is a monoclonal antibody that binds to amyloid-beta protofibrils and promotes their clearance from the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:18:32.404Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia stage with confirmed amyloid pathology)"}]},"trialDetails":[{"nctId":"NCT04468659","phase":"PHASE3","title":"AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Inc.","startDate":"2020-07-14","conditions":"Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease","enrollment":1400},{"nctId":"NCT06384573","phase":"PHASE3","title":"DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-06-10","conditions":"Alzheimer's Disease, Dementia, Alzheimer's Disease, Familial","enrollment":40},{"nctId":"NCT06602258","phase":"PHASE2","title":"A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Inc.","startDate":"2024-09-30","conditions":"Alzheimer's Disease","enrollment":105},{"nctId":"NCT03887455","phase":"PHASE3","title":"A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Inc.","startDate":"2019-03-27","conditions":"Early Alzheimer's Disease","enrollment":1906},{"nctId":"NCT05045716","phase":"PHASE1","title":"A Study of Subcutaneous Lecanemab in Healthy Participants","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2021-09-07","conditions":"Healthy Volunteers","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BAN2401"],"phase":"phase_3","status":"active","brandName":"Lecanemab IV","genericName":"Lecanemab IV","companyName":"Eisai Inc.","companyId":"eisai","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lecanemab is a monoclonal antibody that binds to amyloid-beta protofibrils and promotes their clearance from the brain. Used for Early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia stage with confirmed amyloid pathology).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}